Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Puma Biotechnology (PBYI)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE) and Puma Biotechnology (PBYI).

SAGE Therapeutics (SAGE)

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on SAGE Therapeutics today and set a price target of $87.00. The company’s shares closed last Monday at $60.18, close to its 52-week low of $56.50.

According to TipRanks.com, Tsao is a 1-star analyst with an average return of -1.7% and a 47.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $128.67 average price target, which is a 127.2% upside from current levels. In a report released yesterday, Leerink Partners also upgraded the stock to Hold with a $63.00 price target.

See today’s analyst top recommended stocks >>

Puma Biotechnology (PBYI)

In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Puma Biotechnology and a price target of $15.00. The company’s shares closed last Monday at $7.44, close to its 52-week low of $6.26.

According to TipRanks.com, White is a 5-star analyst with an average return of 20.9% and a 54.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Currently, the analyst consensus on Puma Biotechnology is a Hold with an average price target of $12.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts